|
GB9818732D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collection of compounds
|
|
GB9818731D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Compounds
|
|
GB9818730D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collections of compounds
|
|
WO2000012508A2
(en)
|
1998-08-27 |
2000-03-09 |
Spirogen Limited |
Pyrrolbenzodiazepines
|
|
GB0226593D0
(en)
|
2002-11-14 |
2002-12-24 |
Consultants Ltd |
Compounds
|
|
GB0321295D0
(en)
|
2003-09-11 |
2003-10-15 |
Spirogen Ltd |
Synthesis of protected pyrrolobenzodiazepines
|
|
GB0404577D0
(en)
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
|
PT1720881E
(pt)
|
2004-03-01 |
2013-02-04 |
Spirogen Sarl |
Derivados de 11-hidroxi-5h-pirrolo[2,1-c][1,4]benzodiazepin- 5-ona como intermediários chave para a preparação de pirrolobenzodiazepinas substituídas em c2
|
|
WO2005085260A1
(en)
|
2004-03-09 |
2005-09-15 |
Spirogen Limited |
Pyrrolobenzodiazepines
|
|
GB0819095D0
(en)
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
|
CN103068405A
(zh)
|
2010-04-15 |
2013-04-24 |
西雅图基因公司 |
靶向吡咯并苯并二氮杂卓结合物
|
|
EP2558475A1
(en)
|
2010-04-15 |
2013-02-20 |
Spirogen Sàrl |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
|
GB201006340D0
(en)
|
2010-04-15 |
2010-06-02 |
Spirogen Ltd |
Synthesis method and intermediates
|
|
CN103987718A
(zh)
|
2011-09-20 |
2014-08-13 |
斯皮罗根有限公司 |
作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓
|
|
CA2850373C
(en)
|
2011-10-14 |
2019-07-16 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
JP6170497B2
(ja)
|
2011-10-14 |
2017-07-26 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン
|
|
BR112014008981A2
(pt)
|
2011-10-14 |
2017-05-02 |
Spirogen Sàrl |
pirrolobenzodiazepinas
|
|
WO2013053872A1
(en)
|
2011-10-14 |
2013-04-18 |
Spirogen Sàrl |
Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
|
|
JP6399930B2
(ja)
|
2011-10-14 |
2018-10-03 |
シアトル ジェネティクス，インコーポレーテッド |
ピロロベンゾジアゼピンおよび標的コンジュゲート
|
|
AU2013328625B2
(en)
|
2012-10-12 |
2016-12-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP2906297B1
(en)
|
2012-10-12 |
2017-12-06 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-antibody conjugates
|
|
DK2906298T3
(en)
|
2012-10-12 |
2018-12-17 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
RS57694B1
(sr)
|
2012-10-12 |
2018-11-30 |
Adc Therapeutics Sa |
Pirolobenzodiazepin - anti-psma konjugati antitela
|
|
EP2839860B1
(en)
|
2012-10-12 |
2019-05-01 |
MedImmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
PT3470086T
(pt)
|
2012-10-12 |
2021-02-01 |
Medimmune Ltd |
Pirrolobenzodiazepinas e conjugados das mesmas
|
|
KR101995621B1
(ko)
|
2012-10-12 |
2019-07-03 |
에이디씨 테라퓨틱스 에스에이 |
피롤로벤조디아제핀-항-cd22 항체 컨주게이트
|
|
WO2014057114A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
|
WO2014057072A1
(en)
|
2012-10-12 |
2014-04-17 |
Spirogen Sàrl |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP3054983B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2015052535A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2016083468A1
(en)
|
2014-11-25 |
2016-06-02 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
PL3544636T3
(pl)
|
2017-02-08 |
2021-12-06 |
Adc Therapeutics Sa |
Koniugaty pirolobenzodiazepina-przeciwciało
|
|
SMT202200490T1
(it)
|
2017-04-18 |
2023-01-13 |
Medimmune Ltd |
Coniugati di pirrolobenzodiazepina
|
|
PL3612234T3
(pl)
|
2017-04-20 |
2024-09-02 |
Adc Therapeutics Sa |
Terapia skojarzona z koniugatem anty-AXL przeciwciało-lek
|
|
BR112019026564A2
(pt)
|
2017-06-14 |
2020-06-30 |
Adc Therapeutics Sa |
regimes de dosagem para a administração de um adc anti-cd19
|
|
SMT202200225T1
(it)
|
2017-08-18 |
2022-07-21 |
Medimmune Ltd |
Coniugati di pirrolobenzodiazepina
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
AU2020242747B2
(en)
|
2019-03-15 |
2025-09-18 |
Medimmune Limited |
Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
|